Chemistry

How to Improve the Solubility and Dissolution of Metronidazole

Step-by-step chemistry solution: How to Improve the Solubility and Dissolution of Metronidazole

As an Amazon Associate, I earn from qualifying purchases. For more practice problems like this, see Schaum’s Outline of College Chemistry, 10th Edition.

1. Restating the Question in Plain Language

You need to dissolve metronidazole (a nitro‑imidazole antimicrobial) while you are making a pharmaceutical product.
The problem is that metronidazole has only modest water solubility, so you have to choose a practical technique that will give you a clear, stable solution (or a uniformly dispersed solid) suitable for the intended dosage form (e.g., oral liquid, injectable, or solid tablet).

2. Step‑by‑Step Solution

Below is a systematic “recipe” that any formulation scientist can follow to decide the most appropriate method for improving the solubility and dissolution of metronidazole.

Step What to Do Why it Helps
2.1. Gather the physicochemical data • Molecular weight = 171.15 g mol⁻¹
• Log P ≈ −0.02 (very slightly hydrophilic)
• pK_a (imidazole N‑H) ≈ 2.5 (weak base)
• Water solubility ≈ 10 mg mL⁻¹ (≈ 58 mM) at 25 °C
• Melting point ≈ 160 °C
• Stability: stable from pH 2–9, but degrades faster at high temperature and strong alkaline pH.		 Knowing these values tells you which solubilisation levers (pH, co‑solvent, complexation, particle size) can be used without destroying the drug.
2.2. Define the final dosage form • Oral liquid (syrup, suspension)
• Injectable solution
• Solid oral dosage (tablet, capsule)		 The form dictates the acceptable excipients (e.g., injectable must be sterile, low toxicity) and the required concentration of drug in the final product.
2.3. Decide whether you need a true solution or a dispersion • If a solution is required (e.g., IV/IM injection), you must achieve > 10 mg mL⁻¹ in a clear, sterile liquid.
• If a suspension or solid dosage is acceptable, you can work with a dispersed solid (micronized powder, solid‑dispersion, or cyclodextrin complex).		 This decision narrows the toolbox: co‑solvents & pH‑adjustment for solutions, particle‑size reduction or solid‑dispersion for solids.
2.4. Check the pH‑solubility profile Metronidazole is a weak base; its cationic form (protonated) is more soluble.
• At pH 1–2, solubility rises to ~30 mg mL⁻¹.
• At pH > 6, solubility falls to ~5 mg mL⁻¹.		 If the final product can be formulated at a mildly acidic pH (e.g., oral syrup pH 3–4, injectable pH 4.5–5), simply adjusting the pH with a safe acid (citric‑/phosphoric‑acid) is the easiest first step.
2.5. Screen co‑solvents (GRAS‑listed) Typical pharmaceutical co‑solvents:
• Ethanol (≤ 10 % v/v for oral, ≤ 5 % for injectables)
• Propylene glycol (PG) (≤ 30 % v/v)
• Polyethylene glycol 400 (PEG 400) (≤ 10–15 % w/v)
• Glycerin (≤ 5 % for injectables)
Test solubility in binary mixtures (water + co‑solvent) at 25 °C. Example data:
• 5 % EtOH → ~15 mg mL⁻¹
• 10 % PG → ~20 mg mL⁻¹
• 5 % PEG 400 → ~25 mg mL⁻¹		 Co‑solvents increase the polarity‑matching of the drug and break up water structure, dramatically raising solubility.
2.6. Evaluate surfactants / solubilising agents Non‑ionic surfactants (Polysorbate 80, Cremophor EL) or cyclodextrins (β‑CD, HP‑β‑CD).
• 5 % w/v HP‑β‑CD can raise solubility to ~35 mg mL⁻¹.
• 0.2 % Polysorbate 80 can add ~5–10 % more.		 Surfactants reduce interfacial tension; cyclodextrins form inclusion complexes, especially useful for neutral‑to‑slightly polar drugs like metronidazole.
2.7. Consider particle‑size reduction (micronisation or nanomilling) • Use a jet mill or high‑pressure homogeniser to reach D₅₀ ≈ 2–5 µm (micronised) or < 500 nm (nanomilled).
• Check dissolution rate using USP II paddle method (0.5 % w/v in 0.1 M phosphate buffer, pH 6.8).		 Smaller particles have a larger surface area → faster dissolution. Often combined with a wetting agent (e.g., 0.1 % sodium lauryl sulfate).
2.8. Test solid dispersion techniques • Dissolve metronidazole and a hydrophilic carrier (e.g., PVP K30, HPMC, or Soluplus) in a common solvent (ethanol).
• Remove solvent by spray‑drying or melt‑extrusion.
• Resulting amorphous dispersion can increase apparent solubility 2–3×.		 The drug is trapped in an amorphous matrix that releases quickly upon contact with aqueous media.
2.9. Check for salt formation Metronidazole can form salts with strong acids (e.g., metronidazole hydrochloride) but the commercial drug is already the free base. The hydrochloride salt is more soluble (≈ 50 mg mL⁻¹). If you have access to the salt, use it directly. Salt formation is the classic way to boost solubility for ionisable compounds.
2.10. Choose the optimal combination Typical “best‑practice” for a clear oral/injectable solution:
1. Use metronidazole hydrochloride (if available) or the free base with pH ≈ 3.5 (citric‑acid buffer).
2. Add 5 % PG (or 5 % PEG 400) as a co‑solvent.
3. Add 0.2 % HP‑β‑CD for extra solubilisation (optional).
4. Heat gently to 40 °C while stirring until completely dissolved, then filter (0.22 µm for injectables).
Typical “best‑practice” for a solid oral dosage:
1. Micronise the drug to < 5 µm.
2. Blend with 0.5 % sodium lauryl sulfate (wetting agent) and a hydrophilic carrier (microcrystalline cellulose).
3. Compress into tablets; dissolution will be rapid because of the high surface area.		 The combination above gives a stable, clear solution at a drug load of 10–25 mg mL⁻¹ (suitable for most pediatric/adult oral liquids) while staying within regulatory limits for excipients.
2.11. Verify stability & compatibility • Conduct forced‑degradation (acidic, alkaline, oxidative, thermal) at the chosen pH/co‑solvent levels to ensure metronidazole does not decompose.
• Perform compatibility testing with container/closure (glass vs. plastic) and with other actives.		 Guarantees that the solubilisation method does not compromise drug potency or safety.
2.12. Document the final formulation Example (oral syrup, 100 mL):
• Metronidazole hydrochloride 10 g (≈ 58 mmol)
• Citric‑acid‑sodium‑citrate buffer (pH 3.5) 10 mL
• Propylene glycol 5 mL
• HP‑β‑cyclodextrin 2 g (optional)
• Purified water to 100 mL
Procedure: dissolve all solids in water, add PG, adjust pH, heat to 40 °C, stir 15 min, cool, filter, package.		 Provides a ready‑to‑use recipe for scale‑up.

3. Final Answer – The “Most Appropriate” Method

For a clear, stable liquid formulation (oral syrup or injectable):

  1. Use the hydrochloride salt of metronidazole (or the free base) and adjust the aqueous phase to a mildly acidic pH (≈ 3–4) with a pharmaceutically acceptable acid (citric‑acid/phosphate buffer).
  2. Add a GRAS co‑solvent such as 5 % (v/v) propylene glycol or PEG 400 to further increase solubility.
  3. Optionally include a solubilising cyclodextrin (0.1–0.2 % w/v HP‑β‑cyclodextrin) for concentrations above 15 mg mL⁻¹.

Result: Metronidazole dissolves readily to at least 15–25 mg mL⁻¹, the solution remains clear, is chemically stable at the chosen pH, and uses excipients that are safe for oral and parenteral use.

For solid oral dosage forms: Micronisation (≤ 5 µm) together with a small amount of wetting agent (e.g., 0.5 % sodium lauryl sulfate) or formation of a solid dispersion with a polymeric carrier is the most efficient way to boost dissolution rate.

4. Common Mistakes When Solving This Type of Problem

Mistake Why It Happens Consequence
Ignoring the pKa/pH relationship Assuming the drug is neutral in all media. Misses the easiest solubility boost (acidic pH) and may lead to unnecessarily complex solvent systems.
Using too much co‑solvent Adding > 30 % PG or ethanol without checking toxicity. Exceeds regulatory limits, may cause irritation or incompatibility with packaging.
Choosing a non‑pharmaceutically‑acceptable surfactant Selecting laboratory surfactants (e.g., SDS) that are not approved for oral/injectable use. Formulation cannot be marketed; safety issues.
Neglecting stability at the chosen pH Focusing only on solubility and ignoring degradation kinetics. Drug may degrade during storage, leading to loss of potency.
Skipping compatibility testing Assuming all excipients are mutually inert. Unexpected precipitation, colour change, or loss of efficacy after mixing.
Relying on a single method Using only co‑solvent or only pH adjustment. May not achieve the needed drug load; combination approaches are often required.
Forgetting to filter the final solution Believing the solution is sterile after dissolution. Presence of undissolved particles can cause dosing inaccuracies and safety concerns.

Avoiding these pitfalls ensures a robust, scalable, and regulatory‑compliant formulation of metronidazole.

Original question: How to Improve the Solubility and Dissolution of Metronidazole on Chemistry Stack Exchange, licensed CC BY-SA.

More Chemistry Problems